Tryton Medical: Going Against the Flow in Bifurcated Stents
Executive Summary
Many device companies, large and small, have tried unsuccessfully to come up with a stent to treat bifurcated lesions, primarily by focusing on treating the main vessel. Tryton is taking a different approach: using a bare-metal device designed to treat the side branch. The company believes this contrarian strategy pairs perfectly with current drug-eluting stents, making them an ideal acquisition target for a large CV company.
You may also be interested in...
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Stentys' Shifting Focus: Moving Beyond Bifurcations, Stenting for AMI
Launched to develop a better stent for treating bifurcated lesions, Stentys discovered its device appears to be effective in treating a larger unmet clinical need: acute myocardial infarction. This strategy shift holds great promise, but the company must convince physicians that its self-expanding stent will succeed where others have failed, and that it is superior to traditional stents from the major cardiovascular players.